Vivo Capital related stories
All articles and analysis
Biohaven Pharmaceutical files to go publicNew Haven, Connecticut-based Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company targeting neurological diseases, has filed for an $100 million IPO, according to an SEC filing https://www.sec.gov/Archives/edgar/data/1689813/000104746917002426/a2231694zs-1.htm Biohaven has applied to list the stock on the New York Stock Exchange under the ticker symbol "BHVN." Morgan Stanley, Piper Jaffray and Barclays are the lead underwriters. Biohaven's shareholders include Portage Biotech Inc, Vivo Capital and RA Capital.
- VC-backed Verona Pharma files for IPO
London-based Verona Pharma, a biopharmaceutical company, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. Verona plans on listing the stock on the NASDAQ under the ticker symbol "VRNA." Jefferies and Stifel are serving as the lead underwriters. Verona Pharma's backers include Vivo Capital, OrbiMed, New Enterprise Associates, Abingworth, Henderson Global Investors and Aisling Capital.
- Biohaven closes second tranche of $80 mln private placement
Biohaven Pharmaceutical Holding Company Ltd, a clinical stage biopharmaceutical company targeting neurological diseases, including rare disorders, has closed the second tranche of its $80 million private placement. Venrock was the lead investor. Other participants in the financing included Vivo Capital, RA Capital Management, Aisling Capital, Rock Springs Capital, John W. Childs, Greg Bailey, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations and Litmore Capital.
Angiotech Pharmaceuticals to be acquired by Vivo, ZQ-led groupCanadian medical device company Angiotech Pharmaceuticals Inc has agreed to be bought by a consortium led by U.S. healthcare investment firm Vivo Capital and China's ZQ Capital. The latter are joined by GSO Capital Partners, China Orient Asset Management (International) Holding and Fung Shing Investments. Terms were not released for the deal, which is expected to close in the first quarter of 2016. Vancouver-based Angiotech develops and makes branded, private label, and original equipment manufacturer (OEM) surgical instruments. Its existing investors include Blue Mountain Capital, Courage Capital Management and Cetus Capital.
- NeuroPharma nabs $36 mln Series C
Seattle-based Impel NeuroPharma Inc, which is focused on developing treatments for central nervous disorders, has secured $36 million in Series C funding round. The investors were venBIO, 5AM Ventures and Vivo Capital.
- ReadCoor attracts $23 mln Series A
Boston-based ReadCoor Inc, a panomic spatial sequencing platform provider, has closed $23 million in Series A funding. Decheng Capital led the round with participation from Lilly Asia Ventures, Vivo Capital and Hansjörg Wyss. In conjunction with the funding, Victor Tong, a partner at Decheng Capital and Yuh-geng Tsay, a partner at Vivo Capital, have been appointed to ReadCoor's board of directors.
- SentreHEART bags $35 mln Series D
SentreHEART Inc, a maker of technology for catheter-based, non-implant left atrial appendage closure, has raised $35 million in Series D financing. Deerfield Management Company led the round with participation from other investors that included U.S. Venture Partners, Prospect Ventures, Vivo Capital and Decheng Capital.
- Fortis Therapeutics rakes in $18 mln Series A
San Diego-based Fortis Therapeutics Inc, an immuno-oncology biotech company, has raised $18 million in Series A financing. Avalon Ventures led the round with participation from Bregua Corp, Lilly Asia Ventures, Osage University Partners and Vivo Capital.
- Scintilla Pharma to buy Semnur Pharma
Scintilla Pharmaceuticals Inc, a subsidiary of Sorrento Therapeutics Inc, said Aug 15 that it agreed to buy Semnur Pharmaceuticals Inc for an initial payment of $60 million. Scintilla may also pay another $140 million in cash to Semnur's equity holders upon achievement of certain development, product approval and commercial milestones. Semnur, a specialty pharmaceutical company, is backed by Canaan Partners, Frazier Healthcare and Vivo Capital.
- Tricida picks up $55 mln Series C
South San Francisco-based Tricida, a biopharmaceutical company focused on chronic kidney disease, has raised $55 million in Series C funding. Longitude Capital led the round with participation from Vivo Capital, OrbiMed, Sibling Capital Ventures and Limulus Venture Partners. In conjunction with the funding, Dr. David Hirsch, a managing director at Longitude, has been added to Tricida's board.